Stay updated on Neoadj. Encorafenib/Binimetinib in Melanoma: Clinical Trial
Sign up to get notified when there's something new on the Neoadj. Encorafenib/Binimetinib in Melanoma: Clinical Trial page.

Latest updates to the Neoadj. Encorafenib/Binimetinib in Melanoma: Clinical Trial page
- Check4 days agoChange DetectedA new revision entry v3.7.0 is added to the study's history. The prior revision v3.6.6 is removed from the listed changes.SummaryDifference0.1%

- Check11 days agoNo Change Detected
- Check18 days agoNo Change Detected
- Check25 days agoChange DetectedThe revision history now lists a new latest revision labeled v3.6.6, replacing the previous Revision: v3.6.5 entry in the history log. This reflects a minor page update rather than changes to study data.SummaryDifference0.1%

- Check46 days agoChange DetectedNew history entry dated 2026-08-06 adds a Study Status update and records revision v3.6.5 for the study record. This reflects ongoing maintenance of the official history and the current status of the trial.SummaryDifference0.4%

- Check60 days agoChange DetectedA new revision label, v3.6.4, appears in the page history. This represents an updated version of the study record page and does not modify the underlying study data.SummaryDifference0.1%

- Check74 days agoChange DetectedNew Study Status entry added to the record history on 2026-07-06, with an associated data point on 2026-06-16. An earlier history entry dated 2026-05-29 was removed, affecting the timeline shown for the trial.SummaryDifference0.3%

- Check82 days agoChange DetectedA new revision entry v3.6.3 was added to the study's version history and the previous v3.6.2 entry was removed. This updates the historical record to reflect the latest revision state of the study documentation.SummaryDifference0.1%

Stay in the know with updates to Neoadj. Encorafenib/Binimetinib in Melanoma: Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Neoadj. Encorafenib/Binimetinib in Melanoma: Clinical Trial page.